Shanghai Hile Bio-tech - Asset Resilience Ratio
Shanghai Hile Bio-tech (603718) has an Asset Resilience Ratio of 14.18% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shanghai Hile Bio-tech working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Shanghai Hile Bio-tech's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Shanghai Hile Bio-tech.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Hile Bio-tech's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Shanghai Hile Bio-tech (603718) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥195.62 Million | 14.18% |
| Total Liquid Assets | CN¥195.62 Million | 14.18% |
Asset Resilience Insights
- Moderate Liquidity: Shanghai Hile Bio-tech has 14.18% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Hile Bio-tech Industry Peers by Asset Resilience Ratio
Compare Shanghai Hile Bio-tech's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 23.94% |
|
ChemPartner PharmaTech Co Ltd
SHE:300149 |
Biotechnology | 1.67% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Yantai Zhenghai Bio-Tech Co Ltd
SHE:300653 |
Biotechnology | 59.25% |
Annual Asset Resilience Ratio for Shanghai Hile Bio-tech (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Shanghai Hile Bio-tech.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 18.74% | CN¥210.84 Million ≈ $30.85 Million |
CN¥1.13 Billion ≈ $164.64 Million |
+10.06pp |
| 2024-12-31 | 8.68% | CN¥158.58 Million ≈ $23.21 Million |
CN¥1.83 Billion ≈ $267.32 Million |
-4.14pp |
| 2023-12-31 | 12.82% | CN¥212.48 Million ≈ $31.09 Million |
CN¥1.66 Billion ≈ $242.58 Million |
-2.78pp |
| 2022-12-31 | 15.60% | CN¥236.15 Million ≈ $34.56 Million |
CN¥1.51 Billion ≈ $221.58 Million |
-5.31pp |
| 2021-12-31 | 20.91% | CN¥385.59 Million ≈ $56.42 Million |
CN¥1.84 Billion ≈ $269.85 Million |
-7.23pp |
| 2020-12-31 | 28.14% | CN¥502.73 Million ≈ $73.57 Million |
CN¥1.79 Billion ≈ $261.46 Million |
-3.84pp |
| 2019-12-31 | 31.98% | CN¥544.00 Million ≈ $79.60 Million |
CN¥1.70 Billion ≈ $248.95 Million |
+8.00pp |
| 2018-12-31 | 23.98% | CN¥419.24 Million ≈ $61.35 Million |
CN¥1.75 Billion ≈ $255.87 Million |
-11.96pp |
| 2017-12-31 | 35.94% | CN¥575.66 Million ≈ $84.24 Million |
CN¥1.60 Billion ≈ $234.38 Million |
+4.11pp |
| 2016-12-31 | 31.83% | CN¥471.00 Million ≈ $68.92 Million |
CN¥1.48 Billion ≈ $216.56 Million |
+8.36pp |
| 2015-12-31 | 23.46% | CN¥291.00 Million ≈ $42.58 Million |
CN¥1.24 Billion ≈ $181.50 Million |
-- |
About Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The company offers biochemistry reagents, immunoturbidimetric latex reagents, immune turbidimetry reagents, latex enhanced … Read more